Discovery of a Quinoline-4-carboxamide Derivative with a Novel Mechanism of Action, Multistage Antimalarial Activity, and Potent in Vivo Efficacy.

  • Journal Article
  • Research Support, Non-U.S. Gov't
Journal:
Journal of medicinal chemistry, Volume: 59, Issue: 21
Published:
November 10, 2016
PMID:
27631715
Authors:
Beatriz Baragaña B, Neil R Norcross NR, Caroline Wilson C, Achim Porzelle A, Irene Hallyburton I, Raffaella Grimaldi R, Maria Osuna-Cabello M, Suzanne Norval S, Jennifer Riley J, Laste Stojanovski L, Frederick R C Simeons FR, Paul G Wyatt PG, Michael J Delves MJ, Stephan Meister S, Sandra Duffy S, Vicky M Avery VM, Elizabeth A Winzeler EA, Robert E Sinden RE, Sergio Wittlin S, Julie A Frearson JA, David W Gray DW, Alan H Fairlamb AH, David Waterson D, Simon F Campbell SF, Paul Willis P, Kevin D Read KD, Ian H Gilbert IH
Access Paper
Abstract:

The antiplasmodial activity, DMPK properties, and efficacy of a series of quinoline-4-carboxamides are described. This series was identified from a phenotypic screen against the blood stage of Plasmodium falciparum (3D7) and displayed moderate potency but with suboptimal physicochemical properties and poor microsomal stability. The screening hit (1, EC = 120 nM) was optimized to lead molecules with low nanomolar in vitro potency. Improvement of the pharmacokinetic profile led to several compounds showing excellent oral efficacy in the P. berghei malaria mouse model with ED values below 1 mg/kg when dosed orally for 4 days. The favorable potency, selectivity, DMPK properties, and efficacy coupled with a novel mechanism of action, inhibition of translation elongation factor 2 (PfEF2), led to progression of 2 (DDD107498) to preclinical development.

Courtesy of the U.S. National Library of Medicine